

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 37/64, 31/725	A1	(11) International Publication Number: WO 91/19514 (43) International Publication Date: 26 December 1991 (26.12.91)
(21) International Application Number: PCT/DK91/00145 (22) International Filing Date: 30 May 1991 (30.05.91) (30) Priority data: 1488/90 19 June 1990 (19.06.90) DK (71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK). (72) Inventor; and (75) Inventor/Applicant (for US only) : NORDFANG, Ole, Juul [DK/DK]; Selskovvej 6, DK-3400 Hilleroed (DK). (74) Common Representative: NOVO NORDISK A/S; Patent Department, Novo Allé, DK-2080 Bagsvaerd (DK).	(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, PL, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US. Published With international search report.	
(54) Title: AN ANTICOAGULANT PREPARATION		
(57) Abstract For prophylaxis or treatment of coagulation disorders or cancer an extrinsic pathway inhibitor (EPI) is administered together with heparin or other mucopolysaccharide to the patient. Thereby an increase in coagulant activity is obtained as well as an increase of half-life of injected EPI in plasma.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

AN ANTICOAGULANT PREPARATION

FIELD OF INVENTION

5 The present invention relates to a preparation for treating coagulation disorders or cancer, which preparation comprises a protein with anticoagulant activity and a substance acting synergistically with said protein. The invention further relates to a method of treating coagulation disorders or cancer by means of this preparation.

BACKGROUND OF THE INVENTION

15 Blood coagulation is a complex process involving many activating and inactivating coagulation factors. Anticoagulant proteins are known to be important for regulation of the coagulation process (see B. Lämmle and J. Griffin (Clinics in Haematology 14 (1985), 281-342) and anticoagulants are thus important in the treatment of a variety of diseases, eg thrombosis, myocardial infarction, disseminated intravascular coagulation etc.

25 Thus heparin is used clinically to increase the activity of antithrombin III and heparin cofactor II. Antithrombin III is used for the inhibition of factor Xa and thrombin. Hirudin is used for the inhibition of thrombin and protein C may be used for the inhibition of factor V and VIII.

30 Anticoagulant proteins may also be used in the treatment of cancer. Thus, antistatin has been shown to have antimetastatic properties (J.H. Han et al., Gene 75 (1989), (47-57). Also heparin and warfarin have been shown to possess antimetastatic properties (G.J. Gasic et al.,

Int. Rev. Exp. Pathol. 29 (1985), 173-209).

Coagulation can be initiated through the extrinsic pathway by the exposure of tissue factor (TF) to the circulating blood (Y. Nemerson, Blood 71 (1988), 1-8). Tissue factor is a protein cofactor for FVII/VIIa and binding of tissue factor enhances the enzymatic activity of FVIIa towards its substrates FIX and FX. Placenta anticoagulant protein is able to inhibit tissue factor activity, probably by interfering with TF/FVIIa-phospholipid interaction (S. Kondo et al., Thromb. Res. 48 (1987), 449-459).

Recently a new anticoagulant protein, the extrinsic pathway inhibitor (EPI) has been isolated (Broze et al., Proc. Natl. Acad. Sci. 84 (1987), 1886-1890).

On a molar basis EPI has been shown to be a far more potent inhibitor of TF/FVIIa induced coagulation than the placenta anticoagulant protein (R.A. Gramzinski et al., Blood 73 (1989), 983-989). EPI binds and inhibits FXa and the complex between EPI and Xa inhibits TF/FVIIa (SI Rapaport, Blood 73 (1989), 359-365). EPI is especially interesting as an anticoagulant/antimetastatic agent as many tumor cells express TF activity (T. Sakai et al., J. Biol. Chem. 264 (1989), 9980-9988) and because EPI shows anti-Xa activity like antistatin.

EPI has been recovered by Broze et al. (supra) from HepG2 hepatoma cells (Broze, DK patent application No. 4135/88). The gene for the protein has been cloned and the protein has been shown to consist of 3 tandem Kunitz type inhibitor domains (Broze, DK patent application No. 3907/88). The protein consists of 276 amino acid resi-

dues and has in addition to the three Kunitz type inhibitor domains three potential glycosylation sites at position Asn117, Asn167 and Asn229. The molecular weight indicates that some of these sites are glycosylated. Furthermore, it has been shown that Kunitz domain 2 binds FXa while the first Kunitz domain binds FVIIa/TF (Girard et al., Nature 338 (1989), 518-520). EPI has also been isolated from HeLa cells (DK patent application No. 6199/88) and it was shown that HeLa EPI binds heparin.

DISCLOSURE OF THE INVENTION

The present invention relies on the possibility of increasing the anticoagulant activity and the half-life of injected EPI in plasma (i.e. the period of time when EPI circulates in the blood vessels) by concomitantly administering heparin.

Accordingly, the present invention relates to a pharmaceutical preparation for the prophylaxis or treatment of coagulation disorders or cancer, which comprises an extrinsic pathway inhibitor (EPI) protein and heparin or another mucopolysaccharide together with a pharmaceutically acceptable diluent or vehicle.

Thus, the present invention utilises the finding that EPI is a heparin-binding protein (cf. Danish Patent Application No. 6199/88). Furthermore, studies by Sandset et al. (Thromb. Res. 50, 1988, pp. 803-813) have shown that the natural plasma level of EPI is increased up to two-fold following the subcutaneous injection of heparin. These findings have led the present inventors to assume that circulating heparin prevents the binding

of EPI to heparin-like substances (primarily mucopolysaccharides) on endothelial cell surfaces. Conversely, heparin may also act to release already bound EPI from the endothelium. In any case, it is believed to be essential for the anticoagulant activity of EPI that it is found in the circulation rather than bound to endothelial surfaces. Heparin may therefore be said to exert a synergistic effect on the activity of EPI in that, by binding free EPI or EPI released from the endothelium, it increases the anticoagulant activity of EPI and enables the EPI to circulate in the blood. In vitro studies have shown that heparin increases the activity of antithrombin III (L. Rosenfeld, Biochem. J. 237, 1986, pp. 639-646). However, no increase in the half-life of injected antithrombin III on injection of heparin has been observed, and heparin does not act synergistically with antithrombin III in the case of disseminated intravascular coagulation (cf. B. Blauhut, Thromb. Res. 39, 1985, pp. 81-89).

It should be noted that the present invention provides as well preparations in which the EPI protein is combined with heparin in such a way that the EPI protein is actually bound to heparin before administration, as preparations in which the EPI protein and the heparin are kept in separate containers before use in a form which is adapted to the substantially simultaneous or sequential co-administration of the EPI protein and heparin (e.g. with a content of EPI protein adapted to the intended use of the preparation, and with a content of heparin which is sufficient to bind substantially all the EPI protein to be administered). In the latter case, the EPI protein will be bound to circulating heparin in the blood vessels upon administration of both substan-

ces.

Th coagulati n disorders which are to be treated by means of the preparation of the invention are primarily disorders which require treatment with an anticoagulant. Examples of such disorders are those which are conventionally treated by administering heparin alone, e.g. thrombosis, embolism, infarctions or disseminated intravascular coagulation. The preparation of the invention is also contemplated to be useful in the treatment of cancer. This utility is suggested by the anti-metastatic properties of other anticoagulants such as antistatin (cf. J.H. Han et al., Gene 75, 1989, pp. 47-57), heparin and warfarin (cf. G.J. Gasic et al., Int. Rev. Exp. Pathol. 22, 1985, pp. 173-209).

In the present context, the term "EPI protein" is intended to include not only native, or full-length, EPI but also EPI analogues with affinity for heparin. Examples of such analogues are EPI fragments which include the heparin binding domain (believed to be located within the region of the native EPI molecule from the amino acid residue in position 165 to the C-terminal amino residue in position 276, and more specifically assumed to comprise a region rich in positively charged amino acid residues from Arg246 to Lys265).

The term "another mucopolysaccharide" is intended to include heparin-like substances with the ability to bind EPI. Examples of such substances are sulfated glucosaminoglycans selected from heparan sulfate, dermatan sulfate and protamine sulfate. However, the currently preferred mucopolusaccharide for the present purpose is

heparin, and the invention is explained herein mainly in terms of heparin although this should not be construed as a limitation of the invention to the use of heparin.

5 The preparation of the invention may be compounded in any form which is suitable for parenteral administration (e.g. for intravenous or subcutaneous injection or infusion), for instance by dissolving or suspending the EPI protein and the heparin, either separately or in
10 admixture, as explained above, in sterile water or isotonic saline. The dosage level needed to achieve the desired therapeutic effect is estimated on the basis of the content of native EPI in the blood vessels of healthy individuals and the amount of heparin needed to release it from the endothelium. EPI is present in the blood
15 of healthy individuals in an amount of 50 ng/ml of plasma. Injection of, e.g., 5000 IU of heparin may in theory give rise to the release of EPI from epithelial surfaces to a concentration of up to 500ng/ml of plasma. In order
20 to obtain a significant anticoagulant effect of the EPI protein, it is contemplated that a suitable dosage of EPI (unit dose) may be in the range of about 0.5 -40 mg EPI, i.a. dependent on the type and severity of the condition for which treatment with EPI is indicated. A corresponding suitable dosage of heparin is one which is
25 capable of binding this amount of EPI protein to keep it in circulation. Thus, the dosage of heparin to be co-administered with the EPI protein may be in the range of about 1000-15000 IU per unit dose, such as in the range
30 of 2000-10000 IU per unit dose, in particular about 5000 IU per unit dose.

In another aspect, the present invention relates to a method of treating or preventing coagulation disorders

or cancer, which comprises administering, to a patient in need of such treatment, a therapeutically or prophylactically effective dosage of EPI and heparin.

- 5 In one embodiment of the present method, the administration of the EPI protein may be substantially simultaneous with the administration of heparin. This may, for instance be effected by mixing the EPI protein with heparin prior to administration so that the EPI protein
10 will be administered in a form in which it is bound to heparin, or the EPI protein and heparin may be administered separately by means of a device which makes it possible to administer two substances simultaneously. Finally, either the EPI protein or heparin may be administered
15 first and the other component may be administered immediately after that ("immediately" meaning any period of time up to one minute after administering the first substance).
- 20 In another embodiment, the EPI protein may be administered before the administration of heparin. In this case, it is expected that the EPI protein will circulate for only a brief period of time (typically ten minutes) after which it will be bound to heparin-like mucopolysaccharides on epithelial cell surfaces and thus be inactivated. It is, however, envisaged that, analogously
25 with another blood protein (platelet factor 4; cf. G. Cella et al., Eur. J. Clin. Invest. 17, 1987, pp. 548-554), the bound EPI will be released by the subsequent
30 administration of heparin and bind to the administered circulating heparin instead.

In an alternative embodiment, the EPI protein may be administered after the administration of heparin. In this

case, the EPI protein will be bound to the circulating heparin substantially immediately after administration. In order to obtain the desired synergistic effect of heparin, it is contemplated that the EPI protein may be administered 0-24, preferably 0-2, and most preferably 0-0.5, hours after the administration of heparin.

In the latter two embodiments, the EPI protein and the heparin will be administered separately from separate containers. As indicated above, the EPI may be administered in an amount of 0.5 - 40 mg EPI, and the heparin may be administered in an amount of 1000-15000 IU per unit dose, such as an amount of 2000-10000 IU per unit dose. The coagulation disorders for which the administration of EPI protein and heparin is indicated may be any of those mentioned above.

In a further aspect, the present invention relates to the use of an EPI protein and heparin for preparing a medicament for the prophylaxis or treatment of coagulation disorders or cancer. As discussed in more detail above, the EPI protein may be bound to heparin prior to administration, or the EPI protein and the heparin may be provided in separate containers in a form adapted to the substantially simultaneous or sequential co-administration of EPI protein and heparin.

The following method may be employed to show EPI activity in plasma after administration of the present preparation.

Assay for EPI activity: EPI was measured in a chromogenic microplate assay, modified after the method of Sandset et al., (Thromb. Res. 47 (1989), 389-400). Heat tre-

ated plasma pool was used as a standard. This standard is set to contain 1 U/ml of EPI activity. Standards and samples were diluted in buffer A (0.05 M tris /-0.1 M NaCl / 0.1 M Na-citrate / 0.02% NaN₃ / pH 8.0) containing 2 ug/ml polybrene and 0.2% bovine serum albumin. FVIIa/TF/FX/CaCl₂ combination reagent was prepared in buffer A and contained 1.6 ng/ml FVIIa (Novo-Nordisk a/s), human tissue factor diluted 60 fold (Hjort, Scand. J. Clin. Lab. Invest. 9 (1957), 50 ng/ml FX (Sigma) and 18 mM CaCl₂. The assay was performed in microplate strips at 37°C. 50 ul of samples and standards were pipetted into the strips and 100 ul combination reagent was added to each well. After 10 minutes incubation, 25 ul of FX (3.2 ug/ml) was added to each well and after another 10 minutes 25 ul of chromogenic substrate for FXa (S2222) was added 10 minutes after the addition of substrate. The reaction was stopped by addition of 50 ul 1.0 M citric acid pH 3.0. The microplate was read at 405 nm.

20

Coagulation assays

APTT assay: In the Activated Partial Thromboplastin Time (APTT) assay, 55 µl of plasma incubation mixture was mixed with 55 µl of APTT reagent for 300 seconds at 37°C before 55 µl of 0.025 M CaCl₂ were added, and the coagulation time was measured.

PT assay: In the Prothrombin Time (PT) assay rabbit thromboplastin was dissolved according to the manufacturers instructions and 1 volume of thromboplastin was mixed with 2 volumes of 0.03 M CaCl₂. In the assay 75 µl of incubation mixtures was mixed with 75 µl of throm-

10

boplastin/ CaCl_2 reagent at 37° C before the coagulation time was measured.

5 Dilute tissue factor (dTF) assay: The dTF assay was similar to the PT assay. However, in this assay we used human thromboplastin diluted 7.000 fold in coagulation buffer as opposed to be undiluted rabbit thromboplastin used in the PT assay.

10

EXAMPLE

Demonstration of a synergistic effect in coagulation.

15 Coagulation assays were made on plasma samples with added EPI and/or LMW heparin, alle diluted in coagulation buffer (0.1% bovine serum albumin, 50 mM imidazole, 100 mM NaCl, pH 7.3). One sixth of the total volume was rEPI, 1/20 of the volume was LMW heparin. In samples
20 where some of these reagents were not added, coagulation buffer was added to keep the dilution of plasma constant. All samples were incubated for 15 minutes at room temperature before starting the assay. All clotting times were measured on an ACL 300 R coagulation apparatus
25 from Instrumentation Laboratories, Ascoli Piceno, Italy.

RESULTS

30 The results are shown in Figures 1-3.

From Fig. 1 (APTT assay) it can be seen that addition of 10 $\mu\text{g/ml}$ of rEPI alone increased the APTT coagulation time of normal human plasma by 26 seconds while addition

f LMW heparin (0.4 FXaI U/ml) alone increased the time by 57 seconds. Coincubation of the two components in amounts as mentioned above resulted in a much greater effect namely prolonging the coagulation time by 283 seconds.

Fig. 2 (PT assay) shows that addition of 4 μ g/ml rEPI alone increased the coagulation time of normal plasma by 4.4 seconds while addition of LMW heparin (2 FXaI U/ml) alone increased the time by 10.4 seconds. Coincubation of the two components in amounts as mentioned above prolonged the coagulation time by as much as 141 seconds.

Fig. 3 (dTF assay) shows that addition of 0.8 μ g/ml of rEPI alone increased the coagulation time of normal plasma by 35 seconds while addition of LMW heparin (0.2 FXaI U/ml) alone increased the time by 105 seconds. Coincubation of the two components in amounts as mentioned above prolonged the coagulation time by 341 seconds.

Thus, in all three assays the results show a synergistic effect between rEPI and LMW heparin.

CLAIMS

1. A pharmaceutical preparation for the prophylaxis or treatment of coagulation disorders or cancer, which comprises an extrinsic pathway inhibitor (EPI) protein and heparin or other mucopolysaccharide together with a pharmaceutically acceptable diluent or vehicle.
5
2. A preparation according to claim 1, wherein the EPI protein is bound to heparin.
10
3. A preparation according to claim 1, which comprises EPI protein and heparin in separate containers in a form which is adapted to the substantially simultaneous or sequential co-administration of EPI protein and heparin.
15
4. A preparation according to any of claims 1-3, wherein the EPI protein is present in an amount of about 0.5 - 40 mg.
20
5. A preparation according to any of claims 1-4, wherein the heparin is present in an amount of 1000-15000 IU per unit dose, such as an amount of 2000-10000 IU per unit dose.
25
6. A method of treating or preventing coagulation disorders or cancer, which comprises administering, to a patient in need of such treatment, a therapeutically or prophylactically effective dosage of EPI and heparin.
30
7. A method according to claim 6, wherein the administration of the EPI protein is substantially simultaneous with the administration of heparin.

8. A method according to claim 6, wherein the EPI protein is administered before the administration of heparin.
- 5 9. A method according to claim 6, wherein the EPI protein is administered after the administration of heparin.
- 10 10. A method according to claim 9, wherein the EPI protein is administered 0-24, preferably 0-2, and most preferably 0-0.5, hours after the administration of heparin.
- 15 11. A method according to any of claims 6-10, wherein the EPI is administered in an amount of about 0.5 - 40mg.
- 20 12. A method according to any of claims 6-11, wherein the heparin is administered in an amount of 1000-15000 IU per unit dose, such as an amount of 2000-10000 IU per unit dose.
- 25 13. Use of an EPI protein and heparin for preparing a medicament for the prophylaxis or treatment of coagulation disorders or cancer.
14. Use according to claim 13, wherein the EPI protein is bound to heparin.
- 30 15. Use according to claim 13, wherein the EPI protein and the heparin are provided in separate containers in a form adapted to the substantially simultaneous or sequential co-administration of EPI protein and heparin.
-

INTERNATIONAL SEARCH REPORT

International Application No PCT/DK 91/00145

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC5: A 61 K 37/64, 31/725		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC5	A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched ⁸		
SE,DK,FI,NO classes as above		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	Chemical Abstracts, volume 109, no. 13, 26 September 1988, (Columbus, Ohio, US), Sandset, Per Morten et al.: "Heparin induces release of extrinsic coagulation pathway inhibitor (EPI).", see page 43, abstract 104418c, & Thromb. Res. 1988, 50(6), 803- 813	1,13
P,A	WO, A1, 9102753 (NOVO NORDISK A/S) 7 March 1991, see the whole document	1-5,13-15
A	US, A, 4900723 (WILLIAM A. SCHUMACHER) 13 February 1990, see the whole document	1-3,13-15
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
26th September 1991	1991 -09- 30	
International Searching Authority	Signature of Authorized Officer	
SWEDISH PATENT OFFICE	Elisabeth Carlborg	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	EP, A2, 0048898 (CUTTER LABORATORIES) 7 April 1982, see the whole document --	1,2,13, 14
A	US, A, 4689323 (GAUTAM MITRA ET AL.) 25 August 1987, see the whole document --	1,2,13, 14
A	US, A, 4882318 (ISRAEL VLODAVSKY ET AL.) 21 November 1989, see the whole document -- -----	1,13

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 6-12, because they relate to subject matter not required to be searched by this Authority, namely:

Method for treatment of the human or animal body by therapy. Rule 39 (iv).

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers _____, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the the claims. It is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. PCT/DK 91/00145**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the Swedish Patent Office EDP file as of 91-08-30. The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 9102753	91-03-07	AU-D- 6285290	91-04-03
US-A- 4900723	90-02-13	AU-D- 3316089	89-11-02
		EP-A- 0340008	89-11-02
		JP-A- 2056422	90-02-26
EP-A2- 0048898	82-04-07	AU-B- 553260	86-07-10
		AU-D- 7578581	82-04-08
		CA-A- 1187074	85-05-14
		JP-B- 1053650	89-11-15
		JP-C- 1569840	90-07-10
		JP-A- 57088125	82-06-01
		US-A- 4446126	84-05-01
US-A- 4689323	87-08-25	AU-B- 573262	88-06-02
		AU-D- 3356884	85-04-04
		CA-A- 1240264	88-08-09
		EP-A-B- 0137356	85-04-17
US-A- 4882318	89-11-21	AU-D- 7470587	88-01-07
		EP-A- 0254067	88-01-27
		JP-A- 63088128	88-04-19